Life Sciences Archive » January, 2022

Life Sciences - January, 2022

311 articles

• Taiwanese Pharma Co. Beats Sanctions In AOP Arb. Fight
• Opioid Pills Set Off 'Triple Wave' Of Addiction, Judge Hears
• 9th Circ. Won't Review DEA Letter On Medical Psilocybin Use
• UK Bill Would Waive IP On Pandemic Vaccines, Treatments
• ICE Detainees Seek Booster Shots For Medically Vulnerable
• Celgene, Dr. Reddy's Settle Generic Cancer Drug Row
• Elite Trial Lawyer Switches Sides To A Changing Plaintiffs Bar
• Feds Tell Jury Ex-Drug Co-Op CEO To Blame For Opioid Crisis
• Moderna COVID-19 Vaccine Gets FDA's Full OK
• Mylan Says Fed. Circ. Must Nix Ruling That Upheld Biogen IP
• Pharmacies Can't Get 6th Circ. Review In Ohio Opioid Trial
• Keys To Keeping Law Firm Talent Amid The Great Resignation
• Cardinal Health Pays $13M To Settle Doctor Kickback Claims
• Investors In Pot Co. Aphria Seek Class Cert. In $144M Suit
• Medtronic Accused Of Stealing Rival's Sales Reps, Customers
• Cancer-Focused Biotech Co. Plans $132M IPO In Cold Market
• Medical Imaging CEO Gets 5 Years In Prison For $250M Fraud
• CVS Drug Buyers Ask 9th Circ. For Redo Of $121M Trial
• Patent Specification Concerns Make IPRs Tricky For Drug Cos.
• Drugmakers Won't Get Discovery From Valisure In Zantac MDL
• Indivior Asks Fed. Circ. To Rethink Ax Of Suboxone Patent
• Purdue's Appeal On Ch. 11 Releases Fast-Tracked By 2nd Circ.
• Lab Owners Aim To Duck $24M Medicaid Overpayment Claims
• Immigration Policy Changes Are A Boon To STEM Employers
• Arizona Judge Is Latest To Block Contractor Vax Mandate
• Health Hires: Manatt, Garfunkel Wild
• Ex-CDC Worker's Bias Suit Should Get Spiked, Judge Says
• Pa. Worker Claims He Was Fired For Medical Pot Use
• Alston & Bird Nabs Former FDA Associate Chief Counsel
• Strategies For Coping With Stress In The Legal Profession
• 4 Highlights In Breyer's Legal Legacy For Health, Life Sciences
• Teva Gets Nod For $420M Price-Fixing Deal With Investors
• Fed. Circ. Judge Knocks Justices' Assignor Estoppel Ruling
• 6 Breyer Product, Personal Injury Opinions Attys Should Know
• Judge Says Shkreli's Picasso Can Be Sold To Pay $2.6M Debt
• Walmart Seeks Toss Of Suit Over Crash That Killed Girl Scouts
• The Term: Breyer's Legacy And The Nomination To Come
• Breyer Retiring As Supreme Court Lurches Right
• SymBiosis Claims Biotech Firm's Fraud Led To Its Investment
• 'Street Level' Oxy Pusher Admits Tricking Ex-CEO's Company
• All Pa. Counties Join $26B Opioid Deal Over DAs' Objections
• AGs Ask OSHA For Climate Change Heat Standards
• What You Need To Know About Judge Jackson
• Biden At His Side, Justice Breyer Announces Retirement
• 7th Circ. Dismisses Indiana Univ. Students' Vax Mandate Suit
• Democrats Plan Swift Confirmation Of Breyer Successor
• Fla. Judge Vacates Arbitration Award Over Deposition Texting
• 4th Circ. Backs Toss Of FCA Medicaid Suit Against Allergan
• Mississippi Lawmakers Send Medical Pot Bill To Governor
• EPA Declines To Switch Up Ethylene Oxide Risk Calculation
• Meet The Possible Nominees For Justice Breyer's Seat
• How AI Can Transform Crisis Management In Litigation
• 'Just Do Your Job': Justice Breyer's Legacy Of Pragmatism
• ITC Investigating Alvotech's Humira Biosimilar Imports
• Tribal Corp. IP Suit Highlights Sponsored Research Pitfalls
• 5 Breyer Opinions You Need To Know
• Justice Breyer To Retire From High Court
• Digital Medicine Co. Akili Valued At $1B Via SPAC Merger
• 'Frankly Stunning': Distributors Pan DEA Vet At Opioid Trial
• NY Court Reporters Challenge Courthouse Vax Mandate
• Two Investor Settlements From 2021 Crack Top 100 List
• How Vaccine Mandates Impact Employment Insurance Policies
• Zetia Buyers Should Be Denied Class Cert., Court Told
• Mallinckrodt, Fresenius Reach $14M Deal On Supply Claims
• Rhode Island Inks $91M Opioid Deal With Distributors
• The Insys Case Made History. Why An Exec's Appeal May Not
• Supervisor Relationships Are Key To Beating Atty Burnout
• How New Laws Could Tighten FDA Regulation Of Cosmetics
• AstraZeneca Urges Fed. Circ. To Rethink IP Ruling For Mylan
• Supplement Biz Says Rival Lies About Toxic Ingredients
• Distributor Urges 6th Circ. To Revive Opioid Coverage Suits
• Beyond Big: Smaller, Hyperfocused Firms Still Stand Out
• Bridgepoint Inks $7B Sale Of Material Testing Co. To Temasek
• Drug Distributors' Order Reporting Had Flaws, Expert Testifies
• Calif. Pot Seller's Bid To Nix Conviction Fails At High Court
• Fed. Circ. Upholds Patent App Injunction In Trade Secret Row
• Inovio Fights Investor Class Cert. In COVID-19 Vaccine Suit
• 1st Circ. Affirms Broad Gov't Power To End FCA Suits
• Pharma Cos. Get Bystolic Generic Delay Claims Tossed
• Lionbridge Defeats TransPerfect's Trade Secrets Suit
• Ex-Compliance Boss Walks Fine Line At Oxy Conspiracy Trial
• Calfee Halter Adds 4 IP Attys From Cleveland Boutique
• COVID Fuels Top Firms' Priorities In 2022
• The Leaderboard: Tracking A Firm's Litigation Footprint
• Judge Dyk Explains Takeda Loss In IP Fight Over Hemlibra
• Texas Judge Blocks Vaccine Mandate For Federal Workers
• Ga. Judge Grapples With Pot's Legal Status In Licensing Fight
• IPO Market Gets Off To A Rocky Start In 2022
• Roundup Buyers Seek Up To $45M Economic Loss Settlement
• District Court Won't Hear J&J Talc Unit's Ch. 11 Stay Fight
• $26B Deal Keeps Opioid Files Of J&J, Distributors Out Of View
• DOJ Sues Pharmacist For Filling Illegal Opioid Prescriptions
• How Magistrate Judges Can Help Tame Large Product MDLs
• 'Data-Rich' Sources Can ID Niaspan Class, 3rd Circ. Told
• Lessons From Moderna's COVID Vaccine Patent Dispute
• Slayback Gets PTAB To Wipe Out Schizophrenia Treatment IP
• CORRECTED: College Ex-Dean Admits $651K Fraud Against Student Org.
• Fed. Circ. Backs Toss Of MRI Patent Suit Against Government
• Hedge Fund Priest Fights SEC Ban After Mixed Fraud Verdict
• Paul Hastings Expands DC Life Sciences Consulting Group
• IP Forecast: Minerva, Hologic To Face Off At Fed. Circ. Again
• AOP Orphan Accuses PharmaEssentia Of Arbitration Fraud
• Invisalign Maker Gets PTAB To Invalidate Dental Scanner IP
• EPA Says Fuel Importer Violated Clean Air Act
• Commerce Finalizes Duties On Russian, Indian Polymers
• Feds Urge High Court To Back Doctors' Opioid Convictions
• Covid Tester Escalates BCBS Pay Fight With Antitrust Claims
• Clinical Trial Staffer Gets 30 Months For Research Fraud
• Hemp Group Tells DC Circ. To Keep DEA Hands Off 'Hot' Crops
• GAO Unclear If HHS Is Prepared For Full COVID Vax Duties
• Alsup Mulls $113M Atty Fees In $454M Glumetza Antitrust Deal
• Drug Patent Suits' Novel Theory Tests False Claims Act Limits
• Investors Say Biotech Co. Altered Alzheimer Drug Data
• 4 Consequences Of Gov't Contractor Antitrust Violations
• Latham, Davis Polk Guide Psychedelic Co.'s SPAC Merger
• Venture Wants Atty Fees Over CBD Cream Patent Row
• 6 Maura Healey Cases To Know As Gov. Campaign Launches
• Deals Rumor Mill: Zentiva, Carlyle Group, Acorns Grow
• Starbucks Nixes Vax Rule After High Court Sinks OSHA Order
• Mississippi House Passes Medical Marijuana Legalization Bill
• Sanofi Tells 10th Circ. It Paid $36M To Access EpiPen Market
• Appeals Board Won't Hear Software License Breach Dispute
• Emails In Ex-CEO's Oxy Trial Cut Both Ways On Compliance
• The Hottest FCA Cases And Trends To Watch In 2022
• Access Bio Accused Of Breaching $120M COVID Test Kit Deal
• Drugmakers Want Discovery From Valisure In Zantac MDL
• Ill. COVID-19 Testing Cos. Falsified Results, Minn. AG Says
• What's Next For COVID-Era Emergency Use Medical Devices
• Kaiser Says First-To-File Bar Breaks $1B Medicare Fraud Suits
• FTC Cracks Down On COVID Ad Claims Amid Omicron Surge
• The Rising Demand For Commercial Litigators In 2022
• Canadian Model Wants $50M Allergan Unit Suit To Proceed
• NJ Bankruptcy Judge Undoes Split Of J&J Tort Committee
• Marketer Says Racial Bias Drove Pa. Lab's Contract Breach
• No New Trial For Smith & Nephew Hip Implant Patient
• Feds Want 1st Circ.'s Guidance After Jailed Biotech CEO Dies
• Covington, Latham Craft UCB's Zogenix Buy Of Up To $1.9B
• Purdue Urges 2nd Circ. To Quickly Undo Ch. 11 Plan Rejection
• Gilead Says Counterfeit Ring Swiped Its HIV Drug Branding
• Pharma Biz Lied About COVID-19 Drug's Prospects, Suit Says
• Endo's Newest Opioid Deal Earmarks $65M For Fla.
• Tyson Can't Escape COVID-19 Mandate Suit, Workers Say
• Tribe Says Its Opioid Suit Was Not Harmed By Dropped Claim
• Pharma Co. Gets Partial Win In Cancer Drug Contract Fight
• Antitrust's 1900s Nostalgia In The US And Beyond
• Cancer Nonprofit Exec Embezzled $3.7M, Feds Say
• Unvaccinated Ex-Aegerion Rep Can't Delay 4-Year Fraud Term
• Teva Reaches $420M Deal To End Investors' Price-Fixing Suit
• Ex-CEO's Atty Blasts Feds' 'Sales Over Safety' Oxy Charges
• When Fair Notice Precludes Punitive Damages
• Cox Castle Adds Paul Hastings Enviro Founder In California
• Teligent's 3 Ch. 11 Asset Sales Bring $87M Into Estate
• Teva, Glenmark Must Face Price-Fixing Suit At Same Trial
• 3 Firms Rep ProKidney's $2.64B Go-Public SPAC Deal
• SEC's 'Shadow Trading' Theory Passes Muster With Judge
• PTAB Discretionary Denials Escape High Court Review
• Law360 Names Practice Groups Of The Year
• The Firms That Dominated In 2021
• Pharma Exec's Drug Trafficking Trial Tests Bold Legal Theory
• J&J, New Mexico Ink $44M Opioid Settlement
• Judge Gives J&J Talc Unit's Ch. 11 Dismissal Bid Prominence
• Full Fed. Circ. Won't Revive Juno's $1.2B Cancer Patent Win
• Insys Founder Challenges Opioid Conviction At High Court
• Chinese Cos. Seek Immunity In Dupont IP Criminal Case
• Judge Limits Tolling On Retailer Claims In HIV Generics Suit
• Full Fed. Circ. Told Biogen Ruling Threatens Drug Patents
• Takeda Loses Patent Fight Over Roche's Hemlibra Drug
• Orphan Drug Approval Takeaways From Recent FDA Data
• 'Pharma Bro No More' Shkreli Gets Industry Ban, To Pay $65M
• Ranbaxy Wants Equal Trial Time In 'Bet The Company' MDL
• Health Hires: Manatt, Oscar Health
• Boca Lab Owner Admits To $6.9M Medical Testing Scheme
• Mississippi Senate Advances Medical Pot Legalization Bill
• Takeaways From White Collar Criminal Enforcement In 2021
• Glenmark's Ethics Allegations Against DOJ Rejected
• SEC Wins Claim Atty's Biotech Co. Stock Sales Were 'Charade'
• M&A Ruling Illustrates Limits Of Disclaiming Fraud In Del.
• How In-House Counsel Can Make The Case For Settling Early
• 2nd Circ. Rejects Biotech Investor's Media Defamation Suit
• Sens. Move Forward Nominees For FDA Chief, Labor Dept.
• Deals Rumor Mill: Reddit, Lockheed Martin, ProKidney
• Court OKs Pharma Investors' $12.7M Deal Over Drug Trial
• Alleged Shadow Trader Asks Judge To Halt SEC 'Overreach'
• Cannabis Biopharma Co. Nabs CLO From Suboxone Maker
• Calif. Courts Can't Bar New Prop 65 Suits, 9th Circ. Told
• Activist Investor Starboard Urges Huntsman To Change Board
• Clinical Trial Co. Owner Admits Lying To FDA
• Amazon Buyer Tells 2nd Circ. Diet Pill Suit Must Be Tried
• To Retain Talent, GCs Should Prioritize Mission Statements
• Fed. Circ. Doubts PTAB Erred In Axing Almirall Acne Drug IP
• Arthrex Wants Implant Patent Rematch With New USPTO Chief
• Supplement Co. Inks $1.7M Deal Ending Toxic Drink Claims
• Judge Says Soldiers Should Seek Vax Waiver, Not Sue
• Cooley, Loeb & Loeb Shape $511M Medical Co. SPAC Merger
• Hogan Lovells Lands Baker McKenzie Corporate Pro In Philly
• Ex-Theranos CEO Elizabeth Holmes To Be Sentenced Sept. 26
• 1st Circ. Asks Mass. Court To Weigh In On Heart Valve Suit
• CMS Wants Narrow Coverage For Biogen's Alzheimer's Drug
• Sotomayor, Breyer Scrutinized In Feisty Senate COVID Hearing
• No Sanctions For Eli Lilly In Teva Migraine Drug Patent Row
• Real Estate Rumors: Fifield, Alexandria, Spectrum
• Parents Of Disabled Kids Sue Pa. District To Keep Masks
• Cherokees Drop 'Public Nuisance' Theory In Opioid Bellwether
• Judge Won't Lift Ch. 11 Injunction For J&J Talc Claims
• 7 Ways Patent Litigators Can Leverage Inventor Testimony
• Del. High Court Gets It Right With Opioid Nuisance Ruling
• 9th Circ. Skeptical Of Coverage For Co.'s Opioid Probe Costs
• Top 10 Whistleblowing And Retaliation Events Of 2021
• K&S Adds Former DOJ Litigator To Health Care Practice
• Boston Hospital Workers Urge 1st Circ. To Block Vax Mandate
• 5th Circ. Blasts Court For Sealing Records In Abortion Case
• GoodRx Beats IPO Suit Over Surprise Amazon Competition
• Utah Pot Licensing Suit More Than Adequate, Court Told
• LAPD Workers' COVID-19 Vax Mandate Challenge Tossed
• 3rd Circ. Doubts Merck Worker's Arbitration Award In Pay Row
• Del. High Court Relieves Chubb Of Defending Opioid Suits
• Vineyards' Suit Against Monsanto, BASF Sent To State Court
• Regeneron Wins Access To FDA Docs In Kickback Suit
• High Court Won't Hear Off-Label Ad Suit Against Taro
• Chancery Rejects Fast-Tracking Of $6.7B Arena Merger Suit
• FTC Official Joins Wilson Sonsini's Privacy, Security Practice
• Calif. Gov. Signs Order Barring COVID Test Price-Gouging
• Decision Delayed On Whether Talc Spinoff Stay Shelters J&J
• Ex-Theranos COO May Face Trial Delay Due To COVID Surge
• 11th Circ. Won't Rehear Catalyst's Win In 'Orphan Drug' Case
• 'You Can't Kill Patients': Justices Open To CMS Vaccine Rule
• How Attys For Long Island Counties Notched Opioid Trial Win
• 'Hypothetical' Suit Won't Shield Roche Patents From Review
• Deals Attys Approach JPMorgan Event Cautiously Optimistic
• Venture Firm A16Z Raises $9B For Latest Funds
• Stockholder Sues To Block Pfizer's $6.7B Arena Pharma Buy
• Walgreens' Settlement History Will Stay Out Of SF Opioid Row
• The State Of FDA Regulation Of Software As A Medical Device
• Calif. Says Stopping Pay-For-Delay Ban Went 'Too Far'
• 3rd Circ. Affirms Pharmacy Owner's Tax Fraud Conviction
• Georgia Joins $26B US Opioid Settlement With J&J, Others
• Vitamin C Ruling May Trigger Comity Defense Resurgence
• Purdue Ch. 11 Appeal Can Go To 2nd Circ., NY Judge Rules
• Justices' Texas Abortion Ruling Is Murky On Key Question
• Illumina Investor Sent To Prison During Insider Trading Appeal
• 3 Biotech Firms Kick Off '22 With IPOs Totaling $482M
• Milk Vitamin Patents Surprisingly Soured By Section 101
• Generics Catch A Break With Hikma's Skinny Label Win
• Mallinckrodt Says Ch. 11 Plan Fair For Acthar Claimants
• 3rd Circ. Preview: Constitution, Arbitration Fights Start 2022
• Feds Denied Discovery Stay In Challenge To DOD Vax Mandate
• Workplace Vaccine Rules Take Center Stage At High Court
• Top 5 Drug And Medical Device Legal Issues Of 2021
• States Oppose Purdue's 2nd Circ. Appeal Try In Ch. 11 Case
• Class Attys Get $20M From UnitedHealth ERISA Win
• Hawaiian Airlines Workers Sue To Block Vaccine Mandate
• Mylan Can't Exclude Ex-CEO From EpiPen Antitrust Trial
• How Congressional Oversight May Shift In 2022 And Beyond
• Fla. Court Stays $1B Herbalife Fraud Suit Pending Calif. Deal
• Epstein Becker Adds To Health Care Group In Tenn., Ohio
• Immigrant Says J&J Unit Paid Him Less Than Americans
• Recent Bias Suits Against Law Firms And Lessons For 2022
• Delaware Judge Dismisses Guardant Cancer Test IP Suit
• Fed. Circ. Patent Decisions In 2021: An Empirical Review
• Damages Award Nixed In Child's MMR Vaccine Injury Dispute
• Skadden-Led Stryker Buys $3.09B Health Care Software Maker
• Ex-DEA Official Says Cardinal 'Barely' Monitored For Opioids
• Omicron Surge Reshuffles Patent Trial Plans Once Again
• NJ Judge Pauses SEC's Pharma Insider Trading Suit
• DuPont Escapes NY Water Contamination Claims For Now
• Inside The Top De-SPACs That Didn't Survive 2021's 2nd Half
• Stockholders Sue AmerisourceBergen In Del. Over Opioids
• Teva Urges Judge To Limit Walgreens, CVS Antitrust Claims
• $20M Acquisition Would End Maryland Pot Biz Feud
• Pfizer, Allele Biotech End COVID Vax IP Fight
• 3rd Circ. Says Insurer Must Defend In 5-Hour Energy IP Row
• 4 Takeaways From Elizabeth Holmes' Fraud Verdict
• Nevada Says It's Joining $26B Deal With Opioid Distributors
• Hikma Beats Amarin's 'Skinny Label' Patent Suit
• Texas Abortion Providers Ask Justices To Speed Up SB 8 Suit
• No 'Safe Harbor' For Gene Therapy Found In Hatch-Waxman
• COVID Woes Delay High-Profile Gilead, Samsung IP Trials
• Cannabis Co. Trulieve Escapes Investors' Moldy Pot Suit
• Acthar Claimants Call Mallinckrodt's Ch. 11 Plan Unfair
• Split Fed. Circ. Affirms Novartis' Grip On Gilenya
• Opioid Claims Involving McKinsey Should Be Axed, States Say
• Labcorp To Provide Nursing-Mom Rooms After DOL Probe
• Generic Drug Cos., Takeda Escape Gout Drug Antitrust Suit
• Texas Sues Biden Admin. Over National Guard Vax Mandate
• Nimbus, Bristol-Myers Drop Psoriasis Drug Dispute
• DC Circ. Revives Terror-Funding Case Against AstraZeneca
• Merit Medical's $18.25M Investor Fraud Deal Gets First OK
• GSK Ex-Worker Cops To Trade Secrets Theft
• Boston Scientific Says Dead-End SEC Probe Sinks Stock Suit
• Latham-Led Payroll Software Firm Launches $214M IPO
• Purdue's 2nd Circ. Appeal Request To Get Quick Decision
• U. Of Chicago Prof Pleads Not Guilty To Insider Trading
• 5th Circ. Questions Success Of United Vax Mandate Challenge
• Jury Convicts Ex-Theranos CEO Elizabeth Holmes Of Fraud
• Holmes Jury Tells Judge It's Deadlocked On 3 Of 11 Counts
• Bankruptcy Cases To Watch In 2022
• Associate Hiring Outlook At Law Firms Is Bright For 2022
• Merger Cases, Issues To Watch In 2022
• The Top New Jersey Cases To Watch In 2022
• 2022 Trends And Predictions For Patent Litigation
• The Antitrust Conduct Cases To Watch In 2022
• Trademark Cases To Watch In 2022
• A Blockbuster Year Ahead For Health, Life Sciences Litigation
• Buckle Up: Wild Ride Awaits Health, Life Sci Policy In 2022
• Food And Beverage Policy Trends To Track This Year
• Product Liability Regulation, Legislation To Watch: 2021
• Patent Litigation Trends To Watch In 2022
• 2022 Trials To Watch: Opioids, Oracle And Theranos Redux
• Patent Cases To Watch In 2022
• Product Liability Cases To Watch In 2022
• What To Watch In 2022: The Biggest IP Cases Coming Up